Indian Patent Office rejects J&J’s HIV drug patent

12-05-2015

Indian Patent Office rejects J&J’s HIV drug patent

Gil C / Shutterstock.com

The Indian Patent Office has rejected Johnson & Johnson subsidiary Janssen Pharmaceutica’s application to patent its HIV drug Edurant (rilpivirine), according to a report by The Financial Express.


Indian Patent office, Janssen, J&J, Cipla, Edurant

LSIPR